Currently, out of the existing stock ratings of Adam Walsh - 70 which are a Buy (86.42%), 10 which are a Hold (12.35%), 1 which are a Sell (1.23%)

Adam Walsh

Work Performance Price Targets & Ratings Chart

Analyst Adam Walsh was covering the Healthcare sector with 142 price targets and ratings displayed on 15 stocks. Previously, Adam Walsh worked at STIFEL.

Adam Walsh's average stock forecast success ratio is 63.52% with an average time for price targets to be met of 243.8 days.

Most recent stock forecast was given on FGEN, FibroGen at 10-Jul-2020.

Wall Street Analyst Adam Walsh

Analyst best performing recommendations are on RETA (REATA PHARMACEUTICALS).
The best stock recommendation documented was for VRTX (VERTEX PHARMACEUTICALS) at 7/18/2017. The price target of $154 was fulfilled within 1 day with a profit of $21.84 (16.53%) receiving and performance score of 165.25.

Average potential price target upside

of $25.02 (24.78%) on ASND (ASCENDIS PHARMA A/S).
of $23.86 (22.27%) on VRTX (VERTEX PHARMACEUTICALS).
of $20.77 (31.87%) on SAGE (SAGE THERAPEUTICS).

CNCE Concert Pharmaceuticals CORT Corcept Therapeutics INSM Insmed DRRX DURECT RARE Ultragenyx Pharmaceutical ALDX Aldeyra Therapeutics PHAS PhaseBio Pharmaceuticals VRTX Vertex Pharmaceuticals GLPG Galapagos NV RETA Reata Pharmaceuticals ASND Ascendis Pharma A/S FGEN FibroGen GLMD Galmed Pharmaceuticals Ltd PTGX Protagonist Therapeutics SAGE Sage Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Stephen Kim (EVERCORE)